Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension

American Journal of Hypertension

Volumn 27, Issue 6, 2014, Pages 873-880

  Zhou, Ming Sheng ^a   Tian, Runxia ^b   Jaimes, Edgar A ^c   Raij, Leopoldo ^b  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

amlodipine; blood pressure; combination ther apy; endothelial function; hypertension; statin

Indexed keywords

ACETYLCHOLINE; AMLODIPINE; ATORVASTATIN; C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; SUPEROXIDE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CCL2 PROTEIN, RAT; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NOS3 PROTEIN, RAT; OLDLR1 PROTEIN, RAT; PYRROLE DERIVATIVE; SALT INTAKE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; GENE EXPRESSION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; HYPERTROPHY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SALT SENSITIVE HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASODILATATION; ANIMAL; BLOOD PRESSURE; COMPARATIVE STUDY; DAHL RAT; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SALT INTAKE; TIME;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; C-REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKERS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; HYPERTROPHY; MALE; NITRIC OXIDE SYNTHASE TYPE III; PYRROLES; RATS, INBRED DAHL; SCAVENGER RECEPTORS, CLASS E; SODIUM CHLORIDE, DIETARY; SUPEROXIDES; TIME FACTORS; VASODILATION;

EID: 84900023214     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt272     Document Type: Article

References (36)

1. Jamerson K, Weber MA, Bakris GL, Dahlèof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
2. Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am JHypertens 2004; 17:167-171.
3. Zhou MS, Jaimes EA, Raij L. Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats, J Cardiovasc Pharmacol 2006; 48:857-861.
4. Batova S, DeWever J, Godfraind T, Balligand JL, Dessy C, Feron O. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc Res 2006; 71:478-485.
5. Briones AM, Rodrâiguez-Criado N, Hernanz R, Garcâia-Redondo AB, Rodrigues-Dâiez RR, Alonso MJ, Egido J, Ruiz-Ortega M, Salaices M. Atorvastatin prevents angiotensin Il-induced vascular remodeling and oxidative stress. Hypertension 2009; 54:142-149.
6. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004; 44:186-190.
7. Hernâandez-Perera O, Pâerez-Sala D, Navarro-Antolâin J, Sâanchez-Pascuala R, Hernâandez G, Dâiaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells, J Clin Invest 1998; 101:2711-2719.
8. Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, Channon KM. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011; 124:335-345.
9. Curran MP. Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. Drugs 2010; 70:192-213.
10. Sever PS, Poulter NR, Dahlof B, Wedel H. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension, J Hypertens 2009; 27:947-954.
11. Delgado-Montero A, Zamorano JL. Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opin Pharmacother 2012; 13:2673-2685.
12. Cohn JN, Wilson DJ, Neutel J, Houston M, Weinberger MH, Grimm R, Jr., Smith DH, Sun W. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens 2009; 22:137-144.
13. Dorval JF, Anderson T, Buithieu J, Chan S, Hutchison S, Huynh T, Jobin J, Lonn E, Poirier P, Title L, Walling A, Tran T, Boudreau G, Charbonneau F, Genest J. Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. Am J Cardiol 2005; 95:249-253.
14. Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004; 4:267-270.
15. Zhou MS, Schulman IH, Raij L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation, J Hypertens 2010; 28:527-535.
16. Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension 2006; 47:81-86.
17. Zhou MS, Adam AG, Jaimes EA, Raij L. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 2003; 42:945-951.
18. Kosaka S, Pelisch N, Rahman M, Nakano D, Hitomi H, Kobori H, Fukuoka N, Kobara H, Mori H, Masaki T, Cervenka L, Matsumura Y, Houchi H, Nishiyama A. Effects of angiotensin II AT(l)-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats, J Pharmacol Sei 2013; 121:95-102.
19. Das R, Burke T, Van Wagoner DR, Plow EE L-type calcium channel blockers exert an antiinflammatory effect by suppressing expression of plasminogen receptors on macrophages. Circ Res 2009; 105:167-175.
20. Ito D, Ito O, Mori N, Muroya Y, Cao PY, Takashima K, Kanazawa M, Kohzuki M. Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats. J Hypertens 2010; 28:2278-2288.
21. Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 2008; 295:F53-F59.
22. Urbonaviciene G, Frystyk J, Flyvbjerg A, Urbonavicius S, Henneberg EW, Lindholt JS. Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease. Int J Cardiol 2012; 160:89-94.
23. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Lèuscher TF, Cardiology UHZS. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998; 31:499-504.
24. Neutel JM, Bestermann WH, Dyess EM, Graff A, Kursun A, Sutradhar S, Yunis C. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study, J Clin Hypertens (Greenwich, Conn) 2009; 11:22-30.
25. Martin-Ventura JL, Munoz-Garcia B, Blanco-Colio LM, Martin-Conejero A, Madrigal-Matute J, Vega M, Ortega L, Serrano J, Egido J. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int Suppl 2008; 111:S71-S74.
26. Martin-Ventura JL, Tunon J, Duran MC, Blanco-Colio LM, Vivanco F, Egido J. Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients, J Am Soc Nephrol 2006; 17:S189-S193.
27. Sever PS, Dahlèof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, Mclnnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
28. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113-118.
29. Wassmann S, Laufs U, Bèaumer AT, Mèuller K, Ahlbory K, Linz W, Itter G, Rèosen R, Bèohm M, Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-1457.
30. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365:2078-2087.
31. Juncos LI, Juncos LA, Garcia NH. The antihypertensive actions of statins: modulation by salt intake. Am J Hypertens 2012; 25:1140-1148.
32. Feldstein CA. Statins in hypertension: are they a new class of antihypertensive agents? Am J Ther 2010; 17:255-262.
33. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress, J Hypertens 2008; 26:494-500.
34. Zhou MS, Kosaka H, Tian RX, Abe Y Chen QH, Yoneyama H, Yamamoto A, Zhang L. L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats, J Hypertens 2001; 19:421-429.
35. Mason RP, Walter MF, Trumbore MW, Olmstead EG, Jr., Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. IMol Cell Cardiol 1999; 31:275-281.
36. Rikitake Y Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005;97:1232-1235.